Healthcare AI agents touch patient records, clinical workflows, and insurance data. AxonFlow detects sensitive identifiers, gates sensitive decisions through human review, and produces audit evidence your compliance team can evaluate.
When an AI agent accesses a patient record, every interaction falls under regulatory scrutiny. Compliance officers need to answer specific questions: what data left the system, who approved the action, and where is the evidence.
Each use case maps to specific AxonFlow capabilities: healthcare-oriented PII detection, HITL approval gates, MCP connector governance, audit trails, and circuit breakers.
AI agents that evaluate prior auth requests against payer criteria. HITL approval gates ensure a human reviewer signs off before high-cost procedures are approved or denied. Every decision is recorded with the reviewer's identity and timestamp.
HITL Approval Audit Trail Policy EnforcementAI-assisted diagnosis and treatment recommendations. AxonFlow detects sensitive identifiers (SSN, date of birth, credit card numbers with Luhn checksum validation) and redacts it before the data reaches the LLM. Full audit trail links each decision to the requesting clinician.
PII Detection PII Redaction Decision AuditAI copilots that draft discharge instructions, appointment reminders, or patient portal responses. PII redaction strips identifiers before the prompt reaches the LLM. The response is logged with the policy verdict so compliance can verify what was sent.
PII Redaction Policy Enforcement Response LoggingAI agents that assign ICD-10 and CPT codes from clinical notes. AxonFlow governs the MCP connectors that access EHR systems, enforcing which fields the agent can read and logging every data access event. Connector-level policies prevent scope creep.
MCP Governance Access Control Connector PolicyAI systems that scan clinical data for safety signals. AxonFlow's circuit breaker halts the agent when anomalous patterns are detected. Evidence export produces a self-contained audit package for FDA post-market surveillance submissions.
Circuit Breaker Evidence Export Post-Market SurveillanceAxonFlow is not a compliance certification. It provides runtime capabilities — detection, gating, logging, and export — that help engineering teams build systems that satisfy regulatory requirements. Your compliance team makes the final determination.
| Regulation | Requirement | AxonFlow Capability |
|---|---|---|
| HIPAA 164.312(a) | Access control — unique user identification, emergency access procedure, automatic logoff, encryption. | Per-decision audit records include authenticated identity (from your IdP via JWT). Policy enforcement gates access at runtime. All data encrypted in transit (TLS) and at rest. |
| HIPAA 164.312(b) | Audit controls — record and examine activity in systems containing ePHI. | Every policy decision produces an structured audit record with decision_id, verdict (allow/deny/redact/escalate), identity, timestamp, and policy_id. Records are queryable via API and exportable as evidence packages. |
| HIPAA 164.312(e) | Transmission security — guard against unauthorized access to ePHI during transmission. | Healthcare-oriented PII detection identifies and redacts sensitive identifiers before LLM or tool calls. Self-hosted deployment lets patient data stay inside your infrastructure boundary. |
| HITECH Act | Breach notification — notify affected individuals and HHS when unsecured PHI is disclosed. | PII detection and redaction reduce disclosure risk at the source. If sensitive identifiers are redacted before reaching the LLM, audit logs provide evidence of what was and was not transmitted. |
| FDA AI/ML SaMD | Predetermined change control plan, performance monitoring, and transparency for AI/ML-based software as a medical device. | Policy versioning tracks every configuration change. Circuit breaker provides automated performance monitoring with halt capability. Decision audit trail provides the transparency record. |
| EU MDR | Post-market surveillance, clinical evaluation, and risk management for medical devices including AI-based software. | Evidence export produces time-bounded audit packages for post-market surveillance. HITL approval gates enforce human oversight for clinical risk decisions. Circuit breaker addresses risk management. |
| EU AI Act Art 13–14 | Transparency (Art 13) and human oversight (Art 14) requirements for high-risk AI systems. | Decision audit trail satisfies transparency requirements — every AI action is recorded with its policy verdict and reasoning. HITL approval gates provide the human oversight mechanism. |
| GDPR Art 17 | Right to erasure — data subjects can request deletion of their personal data. | Erasure API endpoint supports tenant-scoped data deletion requests. Audit records confirm deletion was executed. PII detection reduces the surface area of stored personal data. |
AxonFlow is not a compliance certification product. It provides runtime controls, audit evidence, deployment choices, and human approval paths that security, legal, and platform teams can review before AI reaches sensitive workflows.
Technical documentation for the capabilities referenced on this page. Each link goes to the relevant section of docs.getaxonflow.com.
Start with Community to validate the fit. Move to Evaluation when you need HITL approval gates and evidence export. Talk to us when you need enterprise rollout support.
